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Trichomonas vaginalis (TV) is one of the
most successful protozoan pathogens and
the most common non-viral sexually
transmitted disease, responsible for
around 180 million new infections
worldwide every year.1 Presentation in
females is usually profuse, purulent,
malodorous vaginal discharge and vaginal
irritation, although infection can be
subclinical or asymptomatic.2 TV may also
be associated with inflammation of the
cervix (strawberry cervix) that may
mimic the cervical tenderness associated
with pelvic inflammatory disease (PID).3
Changes in the cervical cells in women
with TV have been likened to the changes
seen in early cervical intraepithelial
neoplasia (CIN), while in men the
infection often presents as urethritis4
and prostatitis.5
For many years, TV infection has been seen
simply as an irritating protozoan that was
relatively easy to treat. Recently, however,
there has been evidence to implicate TV in
pre-term delivery, low birthweight, infant
mortality and predisposition to human
immunodeficiency virus (HIV) infection and
cervical cancer.6 Although all these areas are
interesting, this article will only review the
links between TV and HIV. 
Classical study
T. vaginalis is a classical parasite that harvests
almost all its nutrients and needs from its
host. To accomplish such a task, TV produces
hydrolases to break down host proteins,
oligosaccharides, DNA and lipids to obtain
the building blocks with which to reconstruct
its own macromolecules.7-10
In its quest for these building blocks, 
TV produces a range of highly active enzymes
that also destroy the protective mucin of the
host’s urogenital tract, allowing the TV to
attach to the underlying cells and cause
lesions. These then provide a portal of entry
for HIV, which, under normal circumstances,
does not easily infect females. Indeed,
heterosexual intercourse with a man 
infected with HIV only carries a 1% risk of
HIV transmission. 
Draper et al.11 studied the effect of TV on
secretory leucocyte protease inhibitor (SLPI),
which protects against viral infection, and
found that the inhibitor was non-functional 
in vaginal secretions due to the action of
cysteine proteinases secreted by the
trichomonads. 
Studies from Africa have shown that the
rate of HIV transmission is increased two-fold
in women with TV. In a study in four cities in
sub-Saharan Africa, Buve et al.12 found a
correlation between the prevalence of TV 
and HIV. The prevalence of trichomoniasis
was higher in cities where there were a
higher number of HIV-positive individuals
(31.8%) compared to cities where HIV
incidence was lower (TV prevalence 10.4%).
Sorvillo et al.13 calculated that, if TV infection
amplifies transmission of HIV by a factor of
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Characteristic forms of Trichomonas vaginalis (arrowed) in a liquid-based cytology
preparation from the cervix. 
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two in a country where the prevalence of TV
is 25% (a level common in parts of Africa),
then 20% HIV transmission could be
attributed its presence. 
Taboo subject
From an economic standpoint, treatment of
TV infection is cheap and readily available,
whereas treatment for HIV is outside the
reach of poor communities; thus, diagnosis
and therapy for TV are vital. With reports 
of emerging strains resistant to metronidazole
– the drug of choice for the treatment of TV
infection – fewer patients clear infections and
thus are susceptible to the formation of
lesions, making the penetration of other
sexually transmitted infections (STIs) easier.
Clearly, an understanding of the pathogenicity
of sexually transmitted organisms and their
interactions should allow development of new
diagnostic and treatment regimes. 
Sadly, discussion about STIs remains 
taboo; there is a stigma attached to their
acquisition, and reluctance, both by
governments and individuals, to discuss the
scale of the problem. Nonetheless, it may be
possible to reduce levels of infection through
education and the development of new
treatments. In the UK, however, where there
is access to education, confidential
counselling and screening, and free
medication, there has been an upsurge in the
numbers of cases of STIs reported. 
Continuing quest
In the quest to eradicate sexually transmitted
diseases, including HIV, the UK Medical
Research Council (MRC) will benefit from
funding of some £16 million from the
Department for International Development
over the next five years. In a move likely to
provide a breakthrough in the treatment and
prevention of STIs, government agencies in
the USA allocated $60 million in 2001 for
the development of microbicides and, in the
UK, ML Laboratories is to start an MRC-
funded trial of a product that disrupts
organism binding.14
Such microbicides could provide a safe and
undetectable barrier to infection for women
who currently cannot persuade their partners
to use a condom. An alternative in the form
of the female condom has been singularly
unacceptable and very costly. Thus, the use
of microbicides could bring about a change 
in responsibility for protection and result in
women having the responsibility to safeguard
their sexual health. 
More than just an irritation?
If TV infection predisposes to HIV, does it
also permit access of other viruses to the
urogenital tract? Recent work by Sayed el-Ahl
et al.15 showed that in 48 patients with
invasive cervical cancer and 100 random age-
matched controls, 19% and 5%, respectively,
had antibodies to TV, suggesting that, at some
stage, the cancer patients had contact with
TV. Patients with TV infection had a three-
fold increased likelihood of contracting
cervical cancer, hence TV can be categorised
as an important co-factor in the pathogenesis
of cervical cancer. Since there is a strong
proven link between cervical cancer and
human papillomavirus, is TV a co-factor in
the acquisition of this virus? 
In conclusion, one thing is crystal clear; 
TV is not just an irritating protozoan! 
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